Abstract
This study was undertaken to test the hypothesis that the combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-α- 2b (INF-α) would have a favorable clinical impact on patients with advanced renal cell carcinoma. Fifteen patients were treated with INF-α, 5 million U/m2 three times a week and GM-CSF 5 μg/kg, subcutaneously, daily. Patients received two consecutive 4-week cycles and then restaged. There were no complete responses, two of 15 partial responses (13%), and 13 of 15 had no response (87%). Biological effects (eosinophilia and leukocytosis) were characteristically observed. The therapy was well tolerated, and most side effects were attributable to INF-α. The study failed to show that the addition of GM-CSF to INF-α would increase the response rate in patients with metastatic renal cell carcinoma by enhancement of macrophage tumoricidal activity.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 58-61 |
| Number of pages | 4 |
| Journal | Journal of Immunotherapy |
| Volume | 17 |
| Issue number | 1 |
| State | Published - 1995 |
Fingerprint
Keywords
- Granulocyte-macrophage colony- stimulating factor
- Immunotherapy
- Interferon-α-2b
- Macrophage
- Renal cell carcinoma
ASJC Scopus subject areas
- Cancer Research
- Immunology
- Pharmacology
Cite this
A phase II trial of concomitant interferon-α-2b and granulocyte- macrophage colony-stimulating factor in patients with advanced renal cell carcinoma. / O'Donnell, Robert T; Dea, G.; Meyers, Frederick J.
In: Journal of Immunotherapy, Vol. 17, No. 1, 1995, p. 58-61.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A phase II trial of concomitant interferon-α-2b and granulocyte- macrophage colony-stimulating factor in patients with advanced renal cell carcinoma
AU - O'Donnell, Robert T
AU - Dea, G.
AU - Meyers, Frederick J
PY - 1995
Y1 - 1995
N2 - This study was undertaken to test the hypothesis that the combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-α- 2b (INF-α) would have a favorable clinical impact on patients with advanced renal cell carcinoma. Fifteen patients were treated with INF-α, 5 million U/m2 three times a week and GM-CSF 5 μg/kg, subcutaneously, daily. Patients received two consecutive 4-week cycles and then restaged. There were no complete responses, two of 15 partial responses (13%), and 13 of 15 had no response (87%). Biological effects (eosinophilia and leukocytosis) were characteristically observed. The therapy was well tolerated, and most side effects were attributable to INF-α. The study failed to show that the addition of GM-CSF to INF-α would increase the response rate in patients with metastatic renal cell carcinoma by enhancement of macrophage tumoricidal activity.
AB - This study was undertaken to test the hypothesis that the combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-α- 2b (INF-α) would have a favorable clinical impact on patients with advanced renal cell carcinoma. Fifteen patients were treated with INF-α, 5 million U/m2 three times a week and GM-CSF 5 μg/kg, subcutaneously, daily. Patients received two consecutive 4-week cycles and then restaged. There were no complete responses, two of 15 partial responses (13%), and 13 of 15 had no response (87%). Biological effects (eosinophilia and leukocytosis) were characteristically observed. The therapy was well tolerated, and most side effects were attributable to INF-α. The study failed to show that the addition of GM-CSF to INF-α would increase the response rate in patients with metastatic renal cell carcinoma by enhancement of macrophage tumoricidal activity.
KW - Granulocyte-macrophage colony- stimulating factor
KW - Immunotherapy
KW - Interferon-α-2b
KW - Macrophage
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0028815476&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028815476&partnerID=8YFLogxK
M3 - Article
C2 - 7728306
AN - SCOPUS:0028815476
VL - 17
SP - 58
EP - 61
JO - Journal of Immunotherapy
JF - Journal of Immunotherapy
SN - 1524-9557
IS - 1
ER -